Gastrointestinal Cancers

Certain patients with metastatic colorectal cancer were more likely to have long-term remission to Stivarga treatment, recent research showed.

Imfinzi plus chemotherapy, when given before surgery, improved pathologic complete response rates, regardless of region, in certain patients with gastric or gastroesophageal junction cancers.

Treatment with Opdivo and chemotherapy improved survival in patients with gastrointestinal cancers, compared with chemotherapy alone, according to a phase 3 trial.

Patients with advanced gastric cancers tended to have better survival outcomes when given Opdivo plus chemotherapy, compared to those who were given chemotherapy alone.

As a survivor of colorectal cancer, I expect my scan to say that I’m 99% cancer-free, but it’s the 1% that worries me.

The Food and Drug Administration (FDA) will not be meeting the Jan. 12, 2024 approval deadline for zolbetuximab to treat certain patients with gastric or gastroesophageal junction adenocarcinoma.

Next-generation sequencing was more successful in finding patients with endometrial and colorectal cancer with dMMR disease, indicating that they were eligible for immunotherapy.

Recent research showed that Keytruda plus chemotherapy was superior to placebo plus chemotherapy in GI cancers, although the results were not considered statistically significant.

The RELATIVITY-123 trial evaluating Opdualag in metastatic microsatellite stable colorectal cancer ended prematurely, according to the drug’s manufacturer.

After being diagnosed with cancer, I decided to turn my “whys” and “what ifs” into education and advocacy work.

The Food and Drug Administration approved six new cancer therapies in November 2023.

The Food and Drug Administration approved Keytruda plus chemotherapy for the treatment of patients with advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Keytruda plus chemotherapy for patients with locally advanced biliary tract cancer helped increase survival for up to two more years, an expert told CURE®.

The Food and Drug Administration revised the existing approval of Keytruda, Herceptin and chemotherapy for patients with unresetable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Patients with metastatic colorectal cancer are eligible for treatment with Fruzaqla, an oral targeted therapy, following treatment via fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy as well as an anti-VEGF therapy, and, if their disease RAS wild-type and medically appropriate, an anti-EGFR therapy.

The Food and Drug Administration approved Keytruda plus chemotherapy for patients with locally advanced unresectable or metastatic biliary tract cancer.

Keytruda plus the combination of Herceptin and chemotherapy led to an improvement in progression-free survival versus placebo plus Herceptin and chemotherapy in the first-line treatment of some patients with metastatic HER2-positive gastric or gastroesophageal junction cancer.

The addition of Imfinzi to a chemotherapy regimen called FLOT tended to boost pathologic complete response rates in patients with gastric or gastroesophageal junction cancer.

The combination of Lumakras and Vectibix led to better progression-free survival compared with standard of care in patients with chemorefractory metastatic colorectal cancer harboring KRAS G12C mutations.

A phase 1 trial is being conducted to evaluate the combination of PT886 and Keytruda in patients with claudin 18.2 positive gastric or gastroesophageal junction (GEJ) adenocarcinomas.

Interim findings from the phase 2 ASPEN-06 clinical trial show evorpacept’s potential for treatment of patients with HER2-positive gastric/gastroesophageal junction cancer.

Adding debulking surgery to chemotherapy did not cause a significant decrease in health-related quality of life for patients with metastatic colorectal cancer, research showed.

Findings from the CheckMate 649 trial “further support the use of (Opdivo) plus chemotherapy as a tolerable and efficacious first-line treatment” for some patients, according to researchers.

Battling the unforgiving foe: Cancer.

Treatment combination of Lutathera and Sandostatin improved outcomes for patients with gastroenteropancreatic neuroendocrine tumors.

Treatment of Opdivo and Stivarga plus chemotherapy improves survival in patients with advanced esophageal adenocarcinoma and certain esophageal and stomach cancers.

The second phase of a study evaluating androgen receptor inhibitor masofaniten combined with antiandrogen Xtandi for the treatment of patients with metastatic castration-resistant prostate cancer has been launched.

Vitamin D supplements have been shown to reduce the risk of relapse or death in patients with digestive tract cancer.

A new finding can help predict whether patients with advanced colorectal cancer can benefit from receiving immunotherapy.

At first, I thought I had hemorrhoids, but ended up eventually being diagnosed with anal cancer.